TICKERNERD
Menu
ARDXARDXHealthcare · Biotechnology

ARDX Stock Forecast: Ardelyx, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$3.02
−2.58% on the day

The 11 Wall Street analysts covering Ardelyx, Inc. hold a median 12-month price target of $14 — +347.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 31 Oct 2026 — in the upper half.

Market cap
$782.3M
Ticker Nerd rank
55/ 100
Median analyst target
$14
Analysts covering
11
Revenue$120.9M+23.8% y/y
Operating income−$12.4M
Net income−$16.7M
Free cash flow−$6.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.9%
1M
−11.7%
YTD
−48.2%
1Y
−39.7%
From 52W high
−62.2%
From 52W low
+0.7%
$3.00
$7.99
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ardelyx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
55/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
97
Value
95
Volatility
75
Accruals
62
Size
47
Growth
47
Revisions
43
Issuance
18
Momentum
17

Quality (97): The business earns solid, repeatable profits on what it owns.

Momentum (17): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ARDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26ARDXHigh $18Median $14Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $8Median $14High $18

The green dot is the last close — the median target sits +347.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
19 Aug 2026WedbushReiteratesOutperform$9.00
18 Aug 2026WedbushReiteratesOutperform$9.00
17 Aug 2026Piper SandlerMaintainsOverweight$16 → $15
10 Aug 2026CitigroupMaintainsBuy$14 → $11
10 Aug 2026CitigroupMaintainsBuy—
7 Aug 2026BTIGMaintainsBuy—
7 Aug 2026BTIGMaintainsBuy$17 → $14
7 Aug 2026TD CowenMaintainsBuy$13 → $10
7 Aug 2026TD CowenMaintainsBuy—
16 June 2026Ladenburg ThalmannAssumesBuy$16
23 Feb 2026WedbushReiteratesOutperform—
20 Feb 2026BTIGReiteratesBuy—
20 Feb 2026HC Wainwright & Co.MaintainsBuy—
29 Jan 2026BTIGReiteratesBuy—
21 Jan 2026WedbushMaintainsOutperform—
9 Jan 2026BTIGMaintainsBuy—
9 Jan 2026CitigroupMaintainsBuy—
9 Jan 2026Piper SandlerUpgradeOverweight—
4 Nov 2025Piper SandlerMaintainsNeutral—
3 Nov 2025CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ARDX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ARDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Ardelyx, Inc. returned −39.7% against +12.4% for the S&P 500, dividends included.

ARDX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26ARDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Ardelyx, Inc. (ARDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.6×

Cheaper than 94% of US stocks

Price / sales
1.7×

Cheaper than 55% of US stocks

Price / book
5.1×

Cheaper than 19% of US stocks

EV / EBITDA
−23.5×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
23.8%

Higher than 73% of US stocks

Earnings growth (YoY)
23.8%

Higher than 62% of US stocks

Gross margin
95.2%

Higher than 98% of US stocks

Operating margin
−10.3%

Higher than 24% of US stocks

Net margin
−12.4%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−38.6%

Higher than 25% of US stocks

Return on assets
−4.3%

Higher than 33% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ardelyx, Inc. (ARDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ardelyx, Inc. has a market value of $782.3M and an enterprise value of $755.7M.

  • Revenue in the twelve months to 30 June 2026: $450.9M. The latest quarter grew 23.8% year on year.

  • Net income over the same four quarters: −$55.7M, a −12.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.22.

  • Free cash flow in the twelve months to 30 June 2026: −$17.9M.

  • Shares outstanding: 249.1M.

  • Trailing P/E: −11.6×; forward P/E: 10.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ardelyx, Inc. employs 489 people — $922K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

ARDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARDXArdelyx, Inc.$782.3M55
OABIOmniAb, Inc.$742.9M99
ANNXAnnexon, Inc.$767.8M39
SANASana Biotechnology, Inc.$769.4M36
AVBPArrivent BioPharma, Inc.$733.2M34
DNAGinkgo Bioworks Holdings, Inc.$726.0M43
ACHVAchieve Life Sciences, Inc.$701.2M36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ardelyx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARDX news & analysis

Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

PRNewsWire · 31 Oct 2026negative

Rosen Law Firm reminded purchasers of Ardelyx common stock from January 13, 2025, through August 6, 2026, of a November 16, 2026 deadline to seek lead-plaintiff status in a securities fraud lawsuit. The firm said eligible purchasers may be entitled to compensation through a contingency-fee arrangement, with no out-of-pocket fees or costs.

Why it matters — The notice concerns a securities lawsuit involving ARDX and identifies a deadline for investors who may seek to lead the case.

Ardelyx: Revisiting The Thesis 2 Years On, I'm Surprised At Lack Of Progress

Seeking Alpha · 30 Oct 2026negative

Seeking Alpha maintains a Hold rating on Ardelyx, citing slower revenue growth and reimbursement headwinds despite nearly $500 million in annual revenue. The excerpt says IBSRELA's 2026 guidance was cut to $350–$370 million, XPHOZAH faces Medicare reimbursement challenges, and profitability is targeted for 2027.

Why it matters — The reported guidance reduction and reimbursement challenges temper growth expectations, while reliance on tenapanor and limited pipeline diversification are cited as strategic concerns.

Kaplan Fox Alerts Ardelyx, Inc. (ARDX) Investors to an Approaching Lead Plaintiff Deadline on November 16, 2026

Newsfile Corp · 29 Oct 2026negative

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Ardelyx on behalf of investors who purchased or acquired its common stock from January 13, 2025, through August 6, 2026. The headline notes a lead plaintiff deadline of November 16, 2026.

Why it matters — ARDX watchers may want to note the lawsuit and the stated lead plaintiff deadline.

FAQ

Frequently asked questions about ARDX stock

What is the ARDX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Ardelyx, Inc. have a median 12-month price target of $14, with estimates ranging from $8 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARDX stock a buy right now?

Of the 11 analysts covering Ardelyx, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ardelyx, Inc. 55 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARDX?

As at 31 Oct 2026, Ardelyx, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).

Will ARDX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +347.0% from the last close, and Ticker Nerd's factor model ranks Ardelyx, Inc. 55 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARDX stock forecast for 2030?

No analyst covering Ardelyx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $18 over the next 12 months.

How has ARDX stock performed over the past year?

Ardelyx, Inc. returned -39.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ardelyx, Inc. do?

Ardelyx Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal and cardiorenal diseases.

What is the latest news on ARDX?

The most recent item we track (PRNewsWire, 31 Oct 2026): "Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit". Rosen Law Firm reminded purchasers of Ardelyx common stock from January 13, 2025, through August 6, 2026, of a November 16, 2026 deadline to seek lead-plaintiff status in a securities fraud lawsuit. The firm said eligible purchasers may be entitled to compensation through a contingency-fee arrangement, with no out-of-pocket fees or costs.

Company

About Ardelyx, Inc.

Ardelyx Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal and cardiorenal diseases. The company’s current portfolio centers on tenapanor-based therapies, including IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx also works on therapies for related metabolic and kidney disorders, using its gut-targeted science platform to address conditions that often have limited treatment options. Headquartered in Waltham, Massachusetts, and founded in 2007, Ardelyx serves patients in the United States through direct commercialization and supports broader reach through select partnerships. The company operates in the biotechnology and specialty pharmaceuticals markets, where it contributes prescription treatments designed for chronic, specialist-managed conditions.

CEO Mr. Michael G. Raab · 489 employees · United States · https://www.ardelyx.com